NEW YORK (GenomeWeb News) — Bioconjugation product developer SoluLink today reported it has received $300,000 in venture capital from Plymouth Venture Partners.
 
SoluLink President Steve DeGraw said the investment will enable the company to continue marketing existing products, and to integrate them into new markets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.